natgillin/translations-raw huggingface dataset:
Response to treatment was measured as a reduction in the blood levels of the protein IgM, which is present in high levels in patients with Waldenström’s disease.
Merilo odziva na zdravljenje je bilo znižanje ravni beljakovine IgM, ki je v visoki koncentraciji prisotna pri bolnikih z Waldenströmovo makroglobulinemijo, v krvi.
Response to treatment was measured as complete or partial lack of signs of cancer.
Odziv na zdravljenje so merili kot popolno ali delno odsotnost znakov raka.
Response to treatment with tenofovir disoproxil fumarate was comparable in nucleos(t)ide-naïve (n = 20) and nucleos(t)ide-experienced (n = 32) patients, including lamivudine- resistant patients (n = 6).
Odziv na zdravljenje z dizoproksiltenofovirijevim fumaratom je bil primerljiv v skupini bolnikov, ki se še niso zdravili z nukleoz(t)idi (n = 20) in v skupini bolnikov, ki so se predhodno že zdravili z nukleoz(t)idi/nukleotidi (n = 32), vključno z bolniki, rezistentnimi na lamivudine (n = 6).
Response to treatment with tenofovir disoproxil fumarate was comparable in nucleoside-experienced (n = 51) and nucleoside-naïve (n = 375) patients and in patients with normal ALT (n = 21) and abnormal ALT (n = 405) at baseline when studies GS-US-174-0102 and GS-US-174-0103 were combined.
Pri kombinaciji študij GS-US-174-0102 in GS-US-174-0103 je bil odziv na zdravljenje z dizoproksiltenofovirijevim fumaratom pri bolnikih, ki so bili zdravljeni z nukleozidi (n = 51), in bolnikih, ki še niso bili zdravljeni z nukleozidi (n = 375), ter pri bolnikih z normalno ravnijo ALT (n = 21) in nenormalno ravnijo ALT (n = 405), ob izhodiščni točki, primerljiv.
Response type
Vrsta odziva
Response was also consistent across repeated attacks in the controlled Phase III trials.
Tudi odziv v nadzorovanih preskušanjih 3. faze je bil podoben pri vseh ponavljajočih se napadih.
Response was associated with baseline INI mutation pathway, as shown in Table 5.
Odziv je bil povezan z osnovnim potekom mutacije INI, kot je prikazano v preglednici 5.
Response was defined as:
Odziv je bil definiran kot:
Response week 12 was defined as undetectable HCV- RNA after 12 weeks of treatment.
Odziv v 12. tednu so opredelili kot nemerljivo HCV-RNA po 12 tednih zdravljenja.
Response week 12 was defined as undetectable HCV- RNA after 12 weeks of treatment.
Odziv v 12. tednu so opredelili kot nezaznavno količino HCV-RNA po 12. tednih zdravljenja.
Response Week 24 Week 48
Odziv 24. teden 48. teden
response* (95 % CI)
odgovor* (95-% IZ)
response, but the maximum recommended dose of bupropion should not be exceeded.
odmerek bupropiona ne sme biti
response, n (%) (95%
Popoln TMA odgovor, n (%) (95-% IZ)
Response, Remission and Mucosal Healing in Study UC-II (Percent of Patients)
Odziv, remisija in celjenje sluznice v študiji UC-II (odstotek bolnikov)
Responsea
Odziva
Responses are summarised in Table 5.
Odzivi so prikazani v preglednici 5.
Responses observed in the Simponi treated groups were similar in patients receiving and not receiving concomitant MTX.
Odzivi, ki so jih opazili v skupini bolnikov, zdravljenih z zdravilom Simponi, so bili podobni kot pri bolnikih, ki so sočasno prejemali metotreksat oziroma ga niso prejemali.
Responses of patients with ankylosing spondylitis in a placebo-controlled trial
Odzivi bolnikov z ankilozirajočim spondilitisom v preskušanju, nadzorovanem s placebom
Responses of Patients with Psoriasis in Studies 2, 3 and 4
Odzivi bolnikov s psoriazo v študijah 2, 3 in 4
Responses of Patients with Psoriatic Arthritis in a Placebo- Controlled Trial
Odzivi bolnikov s psoriatičnim artritisom v preskušanju, nadzorovanem s placebom
Responses to IMBRUVICA are shown in Table 2.
Odgovori na zdravilo IMBRUVICA so prikazani v preglednici 2.
Responses to IMBRUVICA are shown in Table 8.
Odgovori na zdravilo IMBRUVICA so prikazani v preglednici 8.
responses were assessed at 5 years in 270 patients with 84% ACR 20 responses, 61% ACR 50 responses, and 40% ACR 70 responses.
Odziv ACR 20 je bil ugotovljen pri 84% bolnikov, odziv ACR 50 pri 61% bolnikov in odziv ACR 70 pri 40% bolnikov.
Responses were measured using ACR Pedi 30 , defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Responses were measured using the ACR Pedi 30 ), defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Responses were measured using the ACR Pedi 30 , defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Responses were measured using the ACR Pedi 30, defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Responses were observed at the first assessment (week 4) after the initial Simponi administration.
Odziv so opazili že pri prvi oceni (v 4. tednu) po prvi uporabi zdravila Simponi.
Responses were observed at the first assessment (week 4) after the initial Simponi administration.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Responses were observed in 13/18 (72%, 95% confidence intervals: 47, 90) of DepoCyte patients versus 3/17 (18% patients, 95% confidence intervals: 4, 43) in the unencapsulated cytarabine arm.
Odziv so opazili pri 13/18 (72 %, 95 % intervali zaupanja: 47, 90) bolnikov, ki so prejemali zdravilo DepoCyte, ter pri 3/17 (18 % bolnikov, 95 % intervali zaupanja: 4, 43) bolnikov, ki so prejemali neinkapsulirani citarabin.
Respreeza 1,000 mg
Respreeza 1.000 mg
Respreeza 1,000 mg powder and solvent for solution for infusion.
Respreeza 1.000 mg prašek in vehikel za raztopino za infundiranje.
Respreeza contains approximately 1.9 mg sodium per ml of reconstituted solution (81 mmol/l).
Zdravilo Respreeza vsebuje približno 1,9 mg natrija na ml rekonstituirane raztopine (81 mmol/l).
Rest of Body
Preostali deli telesa
Rest of drugs
Preostala zdravila
rest period
dan 4
rest period
pre mo r
rest period
pre mor
rest period
pre- mor
rest period
prem or
rest period
premor
restart at 140 mg daily
ponovna uvedba s 140 mg na dan
restart at 280 mg daily
ponovna uvedba z 280 mg na dan
restart at 420 mg daily
ponovna uvedba s 420 mg na dan
restart at 560 mg daily
ponovna uvedba s 560 mg na dan
restart BLINCYTO at 9 mcg/day.
odmerku 9 mcg/dan.
Restart with dose decreased by one level.
Pri nadaljevanju odmerek zmanjšajte za eno raven.
Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours.
Ponovna uvedba zdravil z abakavirjem po sumu na HSR na abakavir lahko povzroči takojšnjo ponovitev simptomov v nekaj urah.
Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours.
Ponovna uvedba zdravil, ki vsebujejo abakavir, po tem, ko se je pojavil sum na preobčutljivostno reakcijo na abakavir, lahko že v nekaj urah povzroči takojšnjo povrnitev simptomov.
Restarting abacavir in such patients must be done in a setting where medical assistance is readily available.
treba pri takšnih bolnikih opraviti v okolju, kjer je takoj na voljo zdravniška pomoč. treba pri takšnih bolnikih opraviti v okolju, kjer je takoj na voljo zdravniška pomoč.
Resting heart rate below 70 beats per minute prior to treatment
rčna frekvenca med mirovanjem pod 70 utripov na minuto pred zdravljenjem
Resting your wrist on the skin near the site, stick the needle at a right angle straight into the skin with a quick, firm motion.
Z zapestjem naslonjenim na kožo v bližini mesta, s hitrim in trdnim gibom zabodite iglo pod pravim kotom naravnost v kožo.
Restless leg syndrome*
sindrom nemirnih nog
restless legs syndrome
indrom nemirnih nog
Restless Legs Syndrome (RLS) in adults that can be associated with discomfort in your legs or arms, urge to move around, sleep disturbance, tiredness or sleepiness during the day.
indroma nemirnih nog (Restless Legs Syndrome - RLS) pri odraslih, ki je lahko povezan z nelagodjem v vaših nogah ali rokah, s potrebo po premikanju, motnjami spanja, utrujenostjo ali zaspanostjo čez dan.
Restless Legs Syndrome, most common adverse reactions
Sindrom nemirnih nog, najpogostnejši neželeni učinki
Restlessness
Nemir
Restlessness
nemir,
Restlessness
Nemirnost
restlessness
nemirnost,
restlessness with increased body movement
nemir s povečanimi telesnimi gibi
restlessness with increased body movement,
nemir z okrepljenimi telesnimi gibi,
restlessness, feeling anxious, sleepiness; shaking and blurred vision.
nemir, občutek tesnobe, zaspanost, tresenje in zamegljen vid.
restlessness, feeling sleepy, or less alert dystonia: This is a condition involving slow or sustained involuntary contraction of muscles.
nemir, občutek zaspanosti ali zmanjšana pozornost distonija: stanje, ki vključuje počasno in neprekinjeno krčenje mišic.
Restlessness.
nemirnost,
restlessness; anxiety; confusion; depression
vznemirjenost, anksioznost, zmedenost, depresija
restlessness; overactivity; short attention span; frustration; mood changes; temper outbursts or explosive behaviour; excessive sensitivity; seriousness or sadness; frequent crying episodes; fearfulness
nemir, prekomerna aktivnost, majhna sposobnost koncentracije, nezadovoljstvo, spremembe razpoloženja, napadi jeze ali vzkipljivost, preobčutljivost, resnost ali žalost, pogost jok in plašnost
Restoration of haemostasis was achieved in 91% of evaluable patients who had serious bleeding and normal haemostasis was observed in 92% of patients who required an urgent procedure.
Ponovna vzpostavitev hemostaze je bila dosežena pri 91 % pregledanih bolnikih, ki so imeli resne krvavitve, normalna hemostaza pa je bila opažena pri 92 % bolnikih, ki so potrebovali nujni poseg.
Restrain the animal’s head, lift the upper lip and insert the needle into the inside of the upper lip until the applicator rests on the lip.
Konju zadržite glavo, dvignite zgornjo ustnico in iglo vbodite na notranji strani zgornje ustnice tako globoko, da se aplikator dotakne njene površine.
Restrain the dog for approximately 2 minutes and avoid contact with the application site for 5 minutes to allow complete drying of the solution.
Držite psa pri miru približno 2 minuti in se izogibajte stiku z mestom nanosa 5 minut, da omogočite popolno osušitev raztopine.
restriction to open surgery and – if the minimum spray distance of 4 cm can be accurately judged – laparoscopy
omejitvi uporabe samo za odprte kirurške postopke in – kadar je mogoče natančno presoditi razdaljo od pršilnika 4 cm – med laparoskopijo;
result in loss of
kinidin
Resulting from its mechanism of action, topotecan is genotoxic to mammalian cells (mouse lymphoma cells and human lymphocytes) in vitro and mouse bone marrow cells in vivo.
Zaradi svojega mehanizma delovanja je topotekan genotoksičen za celice sesalcev (mišje limfomske celice in človeške limfocite) in vitro in celice mišjega kostnega mozga in vivo.
Results 48 week and 96 week analyses
Rezultati 48-tedenske in 96-tedenske analize
Results 48 week and 96 week analyses
Rezultati analiz po 48 in 96 tednih
Results 48-week and 240-week analyses
Rezultati analiz po 48 in 240 tednih
Results according to RET status (positive, unknown and RET M918T mutation negative definition) are presented in Table 3.
Rezultati glede na status RET (določen kot pozitiven, neznan in negativen glede na mutacijo RET M918T) so predstavljeni v Preglednici 3.
Results are available for 150 patients: 101 were randomised to dasatinib and 49 to imatinib (all imatinib-resistant).
Rezultati so na voljo za 150 bolnikov: 101 bolnik je bil randomiziran na dasatinib, 49 bolnikov pa na imatinib (vsi odporni na imatinib).
Results are based on last-observation-carried- forward (LOCF).
Rezultati temeljijo na metodi prenosa zadnjega opazovanja naprej (LOCF).
Results are normally seen within two or three weeks of starting treatment.
Rezultati so običajno vidni po dveh ali treh tednih od začetka zdravljenja.
Results at 26 weeks in a study of Eperzan 30 mg SC weekly (with uptitration to 50 mg weekly if needed) versus sitagliptin (dosed according to renal function) in patients with different degrees of renal impairment
Rezultati po 26 tednih v študiji zdravila Eperzan 30 mg subkutano na teden (z zvišanjem na 50 mg na teden, če je bilo potrebno) v primerjavi s sitagliptinom (odmerjanim glede na delovanje ledvic) pri bolnikih z različnimi stopnjami okvare ledvic
Results at 3 years for the ITT population in the pivotal study*
Rezultati po 3 letih populacije ZNZ v ključni študiji
Results at 48 weeks are presented in the table.
Rezultati v 48. tednu so predstavljeni v tabeli.
Results at 52 weeks in a placebo-controlled study comparing Eperzan 30 mg SC weekly as add-on therapy in patients inadequately controlled on pioglitazone >30 mg daily  metformin >1,500 mg daily
Rezultati (po 52 tednih) s placebom kontrolirane študije, ki je primerjala 30 mg zdravila Eperzan na teden subkutano kot dodatka zdravljenju bolnikov, neustrezno urejenih na pioglitazonu > 30 mg na dan  metforminu > 1.500 mg na dan
Results at 52 weeks in an active-controlled study comparing Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly) to insulin glargine (titrated weekly per prescribing information) as add- on therapy in patients inadequately controlled on metformin  sulfonylurea
Rezultati (po 52 tednih) z aktivno učinkovino kontrolirane študije, ki je primerjala 30 mg zdravila Eperzan na teden subkutano (s fakultativnim zvišanjem na 50 mg na teden) z insulinom glarginom (titriranim tedensko v skladu z informacijami za predpisovanje) kot dodatkom zdravljenju bolnikov, neustrezno urejenih z metforminom  sulfonilsečnino
Results at Week 24 (LOCFa) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products)
Rezultati s placebom kontrolirane študije dapagliflozina v kombinaciji z insulinom (samim ali skupaj s peroralnim antidiabetikom) po 24 tednih (LOCFa)
Results at Week 24 (LOCFa) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products, including metformin)
Rezultati s placebom kontrolirane študije dapagliflozina v kombinaciji z insulinom (samim ali skupaj s peroralnim antidiabetikom, vključno z metforminom) po 24 tednih (LOCFa)
Results at Week 24 (LOCFa) of a placebo-controlled study of dapagliflozin as monotherapy
Rezultati s placebom kontrolirane študije dapagliflozina kot monoterapije po 24 tednih (LOCFa)
Results at Week 52 (LOCFa) in an active-controlled study comparing dapagliflozin to glipizide as add-on to metformin
Rezultati z zdravilno učinkovino kontrolirane študije, ki je primerjala dapagliflozin z glipizidom kot dodatkom k metforminu po 52 tednih (LOCFa)
Results at Week 52 (LOCFa) in an active-controlled study comparing dapagliflozin with glipizide as add-on to metformin
Rezultati z zdravilno učinkovino kontrolirane študije, ki je primerjala dapagliflozin z glipizidom kot dodatkom metforminu po 52 tednih (LOCFa)
Results available from the third study so far show that there was a decrease from 1.99 MS attacks per year to 0.22 in Tysabri-treated patients regardless of which type of disease-modifying treatment they had previously used.
Zaenkrat razpoložljivi rezultati iz tretje študije kažejo na zmanjšanje napadov multiple skleroze iz 1,99 na 0,22 na leto pri bolnikih, zdravljenih z zdravilom Tysabri, ne glede na to, katero zdravilo za spreminjanje poteka bolezni so uporabljali pred tem.
results by 31
rezultati
Results for FEV1, ACQ and AQLQ are shown in Table 4 below for the overall population, and subgroup GINA 4 and 5.
Rezultati za FEV1, ACQ in AQLQ so prikazani v spodnji preglednici 4 za celotno populacijo in za podskupino GINA 4 in 5.
Results for ORR were consistent with that of the investigators’ assessments, 35.3% in the lenvatinib plus everolimus arm, with one complete response and 17 partial responses; no subject had an objective response in the everolimus arm (P < 0.0001) in favor of the lenvatinib plus everolimus arm.
Rezultati za ORR so se ujemali z ocenami raziskovalcev, 35,3 % v skupini z lenvatinibom in everolimusom, z enim popolnim odzivom in 17 delnimi odzivi; noben bolnik ni imel objektivnega odziva v skupini z everolimusom (P < 0,0001) boljšega kot v skupini z lenvatinibom in everolimusom.
Results for secondary endpoints as tested in hierarchical order in the ITT analysis are displayed in Table 3.
Sekundarni končni izidi, preskušani po hierarhičnem vrstnem redu v ITT analizi, so prikazani v preglednici 3.
Results for selected study endpoints at weeks 24 and 48 are shown in the table.
Rezultati izbranih opazovanih dogodkov v študiji v 24. in 48. tednu so prikazani v tabeli.
Results for the main efficacy endpoints at Week 48 and Week 96 are presented in the table below.
Rezultati glavnih opazovanih dogodkov učinkovitosti v 48. in 96. tednu so prikazani v tabeli v nadaljevanju.
results from a Biomarkers research programme including:
programa za raziskovanje biomarkerjev, vključno z:
Results from a clinical drug-drug interaction study conducted with DUAVIVE and from interaction studies with CE or bazedoxifene monotherapy are summarised below.
Rezultati klinične študije medsebojnega delovanja, ki so jo izvedli z zdravilom DUAVIVE, in študij medsebojnega delovanja, ki so jih izvedli s CE ali monoterapijo z bazedoksifenom, so povzeti spodaj.
Results from a clinical study demonstrated a change in sonidegib exposure (32% and 38% decrease in AUC and Cmax) after co-administration of a single dose of Odomzo 200 mg with esomeprazole (a proton pump inhibitor) at 40 mg daily for 6 days in healthy subjects.
Rezultati klinične študije so pokazali, da se je pri zdravih osebah pri sočasni uporabi enkratnega odmerka 200 mg zdravila Odomzo skupaj z esomeprazolom (zaviralcem protonske črpalke) v odmerku 40 mg na dan 6 dni spremenila izpostavljenost sonidegibu (prišlo je do zmanjšanja AUC za 32 % in do znižanja Cmax za 38 %).
Results from a clinical study done on marketed vaccine confirmed the safety profile as observed in the clinical studies.
Rezultati klinične študije, opravljene s cepivom, ki je bilo na trgu, so potrdili varnostni profil, ugotovljen v kliničnih študijah.
Results from a mass balance study with 14C-darunavir with ritonavir showed that approximately 7.7% of the administered dose of darunavir is excreted in the urine unchanged.
Izsledki preskušanja masnega ravnovesja z uporabo s 14C označenega darunavirja z ritonavirjem so pokazali, da se približno 7,7 % danega odmerka darunavirja izloči s sečem v nespremenjeni obliki.
Results from a mass balance study with radioactive 14C-decitabine in cancer patients showed that 90% of the administered dose of decitabine (4% unchanged drug) is excreted in the urine.
Rezultati študije masnega ravnovesja z radioaktivno označenim 14C-decitabinom pri bolnikih z rakom kažejo, da se z urinom izloči 90% apliciranega odmerka decitabina (4% nespremenjene učinkovine).
Results from a mass balance study with radioactive 14C-etravirine showed that < 1.2% of the administered dose of etravirine is excreted in the urine.
Izsledki študije masne bilance s pomočjo radioaktivnega etravirina-C14 so pokazali, da se < 1,2% danega odmerka etravirina izloči s sečem.
Results from a meta-analysis using pooled data from clinical studies with pazopanib show that ALT > 3x ULN was reported in 126/895 (14 %) of patients who did not use statins, compared with11/41 (27 %) of patients who had concomitant use of simvastatin (p = 0.038).
Rezultati metanalize, ki je uporabila združene podatke kliničnih raziskav s pazopanibom so pokazali, da so ALT > 3-kratno zgornjo mejo normalnih vrednosti zabeležili pri 126 od 895 bolnikov (14 %), ki niso uporabljali statinov, in pri 11 od 41 bolnikov (27 %) bolnikov, ki so sočasno uporabljali simvastatin (p = 0,038).
Results from a QWBA (Quantitative Whole Body Autoradiography) study in the rat and the lack of antagonism of CNS opiate effects in humans at naloxegol doses less than 250 mg, indicate minimal distribution of naloxegol into the CNS.
Rezultati študije QWBA (Quantitative Whole Body Autoradiography) pri podganah in odsotnost antagoniziranja opiatnih učinkov v osrednjem živčevju pri človeku ob odmerkih naloksegola manj kot 250 mg kažejo na minimalno porazdelitev naloksegola v osrednje živčevje.
Results from all clinical trials with Toujeo indicated that reductions in HbA1c from baseline to end of trial were non-inferior to insulin glargine 100 units/ml.
Rezultati vseh kliničnih preskušanj z zdravilom Toujeo so pokazali, da znižanje HbA1c od izhodišča do konca preskušanja ni bilo inferiorno v primerjavi z insulinom glarginom 100 enot/ml.
Results from alogliptin studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha- glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.
Rezultati študij z metforminom, s pioglitazonom (tiazolidindion), z voglibozo (zaviralec glukozidaze alfa) in gliburidom (sulfonilsečnina) ne kažejo klinično pomembnih farmakokinetičnih interakcij.
Results from an expanded access program for patients with STS (study ET743-SAR- 3002) show that among the 903 subjects assessed for OS, the median survival time was 11.9 months (95% CI: 11.2, 13.8).
Rezultati programa razširjenega dostopa pri bolnikih s sarkomom mehkega tkiva (študija ET743-SAR- 3002) kažejo, da je med 903 bolniki, pri katerih je bila ocenjena splošna stopnja preživetja, mediana preživetja 11,9 meseca (95-odstotni IZ: 11,2; 13,8).
Results from an in vitro receptor screening study do not indicate a likely interaction with other therapeutic targets or a potential for clinically relevant pharmacodynamic interactions (see section 5.1).
Rezultati in vitro receptorske presejalne študije ne kažejo verjetnega medsebojnega delovanja z drugimi terapevtskimi tarčami ali potenciala za klinično pomembne farmakodinamične interakcije (glejte poglavje 5.1).